Global Oral Biologics Market by Type (Oral Protein Therapeutics, Oral Monoclonal Antibodies, Oral Vaccines), by End-Use Industry (Pharmaceutical & Biotechnology, Healthcare Providers), by Application (Autoimmune Disorders, Cancer Treatment, Infectious Diseases, Inflammatory Diseases); Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Oral Biologics Market was valued at USD 2.2 Billion in 2024-e and will surpass USD 8.8 Billion by 2030; growing at a CAGR of 25.8% during 2025 - 2030.

The Oral Biologics Market is poised for significant growth as the pharmaceutical industry shifts towards more patient-friendly drug delivery systems. Oral biologics, including protein therapeutics, monoclonal antibodies, and vaccines, are transforming the treatment landscape, particularly for chronic conditions and infectious diseases. The convenience of oral administration over traditional injection methods is a major factor driving this market. As innovations in formulation and technology make oral biologics more effective and stable, the market is witnessing an increasing demand across healthcare providers, pharmaceutical companies, and biotechnology firms.

Oral Protein Therapeutics Segment Is Largest Owing to Therapeutic Versatility

The oral protein therapeutics segment is the largest in the oral biologics market due to the broad therapeutic applications of protein-based drugs. Oral protein therapeutics, which include enzymes, hormones, and growth factors, are used to treat a variety of conditions such as diabetes, hemophilia, and metabolic disorders.

These therapeutics offer the significant advantage of bypassing the need for injections, making treatment more convenient and improving patient adherence. As protein drugs become more stable and effective in oral form, they are increasingly being utilized in both chronic disease management and acute conditions, establishing oral protein therapeutics as the dominant category in this market.

Oral Monoclonal Antibodies Segment Is Fastest Growing Owing to Advances in Drug Formulation

Oral monoclonal antibodies represent the fastest-growing segment of the oral biologics market, propelled by significant advancements in drug formulation and delivery technologies. Monoclonal antibodies, which have traditionally been administered through injections or infusions, are now being developed in oral formulations to offer patients a more convenient alternative for treating conditions such as cancer and autoimmune diseases.

These advancements are particularly critical for conditions that require long-term or repeated treatments, as oral administration improves patient comfort and compliance. The growing clinical success of oral monoclonal antibodies is accelerating their uptake in therapeutic areas, leading to rapid market growth for this segment.

Autoimmune Disorders Segment Is Largest Application Owing to High Prevalence and Need for Long-Term Management

The autoimmune disorders application segment is the largest within the oral biologics market, driven by the high prevalence of conditions like rheumatoid arthritis, multiple sclerosis, and Crohn's disease, which require ongoing treatment. Oral biologics offer significant advantages in managing these chronic conditions, providing patients with more accessible and manageable treatment options.

Oral therapies for autoimmune disorders are designed to modulate the immune system, reducing inflammation and preventing disease progression. The shift towards oral delivery systems for these conditions is expected to improve patient adherence, reduce treatment burden, and enhance overall outcomes, contributing to the dominance of this application in the oral biologics market.

Pharmaceutical & Biotechnology Segment Is Largest End-Use Industry Owing to Innovation and R&D Investment

The pharmaceutical and biotechnology industry is the largest end-use sector for oral biologics, driven by the substantial investments in research and development to create new, more effective oral biologic therapies. Pharmaceutical and biotech companies are at the forefront of developing innovative formulations that allow for the effective delivery of biologic drugs in oral form.

These companies play a critical role in advancing oral biologics for a range of therapeutic areas, from autoimmune disorders to cancer treatment. The extensive resources dedicated to R&D, clinical trials, and manufacturing capabilities make the pharmaceutical and biotechnology industry the leading end-user for oral biologics, as they seek to meet the growing demand for oral therapies.

North America Is Largest Region Owing to Advanced Healthcare Infrastructure and High R&D Investment

North America leads the oral biologics market, driven by its advanced healthcare infrastructure, high rates of chronic disease prevalence, and significant investments in pharmaceutical R&D. The region's robust healthcare systems, supported by a strong focus on patient-centric solutions, make it the largest market for oral biologics.

In addition, North America is home to leading pharmaceutical and biotechnology companies that are spearheading the development of oral biologics for a range of therapeutic areas. Ongoing clinical trials, regulatory advancements, and the region’s commitment to healthcare innovation further contribute to North America's dominance in the market.

Competitive Landscape and Key Players

The Oral Biologics Market is highly competitive, with key players such as AbbVie, Eli Lilly, and Johnson & Johnson leading the way in the development and commercialization of oral biologic products. These companies are focusing on advancing oral formulations of monoclonal antibodies, protein therapeutics, and vaccines to expand their portfolios and improve patient adherence.

The competitive landscape is characterized by continuous innovation, with companies heavily investing in R&D to overcome the challenges of oral biologic delivery, such as drug stability and bioavailability. Strategic partnerships, acquisitions, and collaborations with research institutions are common as companies strive to advance their oral biologic offerings and capture a larger share of the growing market.

Recent Developments:

• Pfizer Inc. launched a new oral biologic drug aimed at treating autoimmune diseases, enhancing patient accessibility to biologic therapies.
• Novartis AG announced the successful completion of clinical trials for an oral monoclonal antibody targeting specific cancer cells.
• Amgen Inc. entered a partnership with a biotech firm to co-develop oral protein therapeutics for inflammatory diseases.
• Johnson & Johnson received approval for its first oral biologic medication for the treatment of rheumatoid arthritis, marking a significant milestone in their biologic portfolio.
• Merck & Co., Inc. acquired a company specializing in oral vaccine technologies, expanding its offerings in the infectious diseases market.

List of Leading Companies:

• Novartis AG
• Pfizer Inc.
• Johnson & Johnson
• AbbVie Inc.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• Merck & Co., Inc.
• Roche Holding AG
• Amgen Inc.
• Sanofi S.A.
• Gilead Sciences, Inc.
• GlaxoSmithKline PLC
• Regeneron Pharmaceuticals, Inc.
• Takeda Pharmaceutical Company Limited
• Vertex Pharmaceuticals Incorporated

Report Scope: